Becton, Dickinson and Company BDX Interventional — Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Becton, Dickinson and Company in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Becton, Dickinson and Company's interventional — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Becton, Dickinson and Company's interventional — revenue?
- Becton, Dickinson and Company (BDX) reported interventional — revenue of $1.36B in Q1 2026.
- How has Becton, Dickinson and Company's interventional — revenue changed year-over-year?
- Becton, Dickinson and Company's interventional — revenue increased by 7.4% year-over-year, from $1.26B to $1.36B.
- What is the long-term trend for Becton, Dickinson and Company's interventional — revenue?
- Over 4 years (2021 to 2025), Becton, Dickinson and Company's interventional — revenue has grown at a 5.3% compound annual growth rate (CAGR), from $4.24B to $5.22B.
- What does interventional — revenue mean?
- This metric represents the total gross sales generated by the Interventional business segment, which focuses on surgical and interventional medical devices. It serves as a primary indicator of the segment's market demand and revenue-generating capacity within the broader medical technology portfolio.